Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cactus Acquisition Corp. 1 LtdCCTSU · Entity 88589 | Chief Financial Officer | October 28, 2021 | November 03, 2021 |
| Gamida Cell Ltd.GMDA · Entity 94655 | Director | January 31, 2024 | February 02, 2024 |
| MediWound Ltd.MDWD · Entity 296 | Director | March 18, 2026 | March 18, 2026 |
| PALATIN TECHNOLOGIES INCPTN · Entity 7649 | Executive VP and CFO/COO | July 15, 2026 | July 17, 2026 |
| Viskase Holdings, Inc.ENZN · Entity 7040 | Director | January 07, 2025 | January 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cactus Acquisition Corp. 1 Ltd
Report date October 28, 2021 · Filed November 03, 2021
This filing explicitly reported no securities owned.
Gamida Cell Ltd.
Report date January 31, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 256,177 |
Reported balance
After 2024-01-31 transaction · row 1
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 200,000 · Balance 256,177 F1: Represents a restricted share unit award, which shall vest on January 31, 2025, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit award, which shall vest on January 31, 2025, subject to the Reporting Person's continuous service through such vesting date.
MediWound Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary sharesSEC Table I · non-derivative | Direct | 9,679 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 9,679 |
| Ordinary sharesSEC Table I · non-derivative | Direct | 750 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 750 F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $34.43 · Expires 2029-03-24 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.25 · Expires 2030-06-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $37.52 · Expires 2031-06-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $14.42 · Expires 2032-05-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 · Expires 2033-05-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2034-02-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.54 · Expires 2035-02-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2036-03-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F2: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
F2: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
PALATIN TECHNOLOGIES INC
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,792 |
Ending reported balance
After 2026-07-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-15 · Tax withholding · Disposed 22 · Balance 63,965 F1: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $11.77 determined as of June 22, 2026, the date of vesting, for a grant of 79 shares less the 22 shares withheld. Row 2 · 2026-07-15 · Tax withholding · Disposed 79 · Balance 63,886 F2: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $11.72 determined as of June 20, 2026, the date of vesting, for a grant of 287 shares less the 79 shares withheld. Row 3 · 2026-07-15 · Tax withholding · Disposed 94 · Balance 63,792 F3: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $14.34 determined as of June 4, 2026, the date of vesting, for a grant of 345 shares less the 94 shares withheld. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $11.77 determined as of June 22, 2026, the date of vesting, for a grant of 79 shares less the 22 shares withheld.
F2: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $11.72 determined as of June 20, 2026, the date of vesting, for a grant of 287 shares less the 79 shares withheld.
F3: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $14.34 determined as of June 4, 2026, the date of vesting, for a grant of 345 shares less the 94 shares withheld.
Viskase Holdings, Inc.
Report date January 07, 2025 · Filed January 10, 2025
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DERMA SCIENCES, INC.
Report date February 24, 2017 · Filed February 24, 2017
Section 16 reporting ended · disclosed 2017-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,500 |
Ending reported balance
After 2017-02-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-02-24 · Disposition to issuer · Disposed 147,076 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2017, by and among the Issuer, Integra Derma, Inc. and Integra LifeSciences Holdings Corporation (the "Merger Agreement"), as of the Effective Time (as defined in the Merger Agreement), the shares of the Issuer's common stock were converted into the right to receive $7.00 per share to the reporting person in cash. Row 2 · 2017-02-24 · Disposition to issuer · Acquired 27,500 · Balance 27,500 F2: Represents shares of the Issuer's common stock received upon the vesting of 27,500 restricted stock units, as described herein. F4: In connection with the expiration of the Offer and the subsequent closing of the merger pursuant to the terms of the Merger Agreement, all outstanding stock options became fully vested and exercisable on such date. Each stock option held by the reporting person was then cancelled in exchange for a cash payment representing the difference between the exercise price of such option and $7.00 per share, payable without any interest thereon and subject to any required tax withholdings. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 | Direct | 0 |
Reported balance
After 2017-02-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-24 · Disposition to issuer · Disposed 29,375 · Balance 0 F3: Represents the weighted average exercise price for in-the-money stock options, as described in a Schedule TO and the Issuer's Schedule 14D-9, each as filed with the Securities and Exchange Commission on January 25, 2017, pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share (the "Offer"). F6: The options were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration. F4: In connection with the expiration of the Offer and the subsequent closing of the merger pursuant to the terms of the Merger Agreement, all outstanding stock options became fully vested and exercisable on such date. Each stock option held by the reporting person was then cancelled in exchange for a cash payment representing the difference between the exercise price of such option and $7.00 per share, payable without any interest thereon and subject to any required tax withholdings. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-02-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-02-24 · Disposition to issuer · Disposed 27,500 · Balance 0 F5: Upon the Effective Time, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings. F7: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2017, by and among the Issuer, Integra Derma, Inc. and Integra LifeSciences Holdings Corporation (the "Merger Agreement"), as of the Effective Time (as defined in the Merger Agreement), the shares of the Issuer's common stock were converted into the right to receive $7.00 per share to the reporting person in cash.
F2: Represents shares of the Issuer's common stock received upon the vesting of 27,500 restricted stock units, as described herein.
F3: Represents the weighted average exercise price for in-the-money stock options, as described in a Schedule TO and the Issuer's Schedule 14D-9, each as filed with the Securities and Exchange Commission on January 25, 2017, pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share (the "Offer").
F4: In connection with the expiration of the Offer and the subsequent closing of the merger pursuant to the terms of the Merger Agreement, all outstanding stock options became fully vested and exercisable on such date. Each stock option held by the reporting person was then cancelled in exchange for a cash payment representing the difference between the exercise price of such option and $7.00 per share, payable without any interest thereon and subject to any required tax withholdings.
F5: Upon the Effective Time, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings.
F6: The options were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration.
F7: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2022 Filed Jun 24, 2022 23:32 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 47,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-008784 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,156,557 F2 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. F2 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:32 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 395,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-008784 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,109,100 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2023. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2023. Read SEC document |
| August 13, 2021 Filed Aug 13, 2021 21:04 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | Tax withholdingCommon stock | 12,421 | $0.56 | $6,955.76 |
DisclosureSEC source: 0001654954-21-008931 · section16.xml · nonDerivative · entry 4 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,640,464 F4 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant and vesting of the underlying 45,199 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021. F4 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant and vesting of the underlying 45,199 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021. Read SEC document |
| August 13, 2021 Filed Aug 13, 2021 21:04 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | Tax withholdingCommon stock | 13,847 | $0.56 | $7,754.32 |
DisclosureSEC source: 0001654954-21-008931 · section16.xml · nonDerivative · entry 3 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,652,885 F3 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant of the underlying 50,500 time-based restricted share units which vested on June 24, 202, was reported on Form 4 filed on June 26, 2019. F3 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant of the underlying 50,500 time-based restricted share units which vested on June 24, 202, was reported on Form 4 filed on June 26, 2019. Read SEC document |
| August 13, 2021 Filed Aug 13, 2021 21:04 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | Tax withholdingCommon stock | 29,782 | $0.56 | $16,677.92 |
DisclosureSEC source: 0001654954-21-008931 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,666,732 F2 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant and vesting of the underlying 108,615 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021. F2 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant and vesting of the underlying 108,615 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021. Read SEC document |
| August 13, 2021 Filed Aug 13, 2021 21:04 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | Tax withholdingCommon stock | 38,182 | $0.56 | $21,381.92 |
DisclosureSEC source: 0001654954-21-008931 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,696,514 F1 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant of the underlying time-based restricted share units, which vest at the rate of 25% per year starting June 16, 2021, was reported on Form 4 filed on June 18, 2020 as to one half of the total grant, and on Form 4 filed on June 26, 2020 as to the remaining one half, which had been granted contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved the stockholders at a meeting on June 25, 2020. F1 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant of the underlying time-based restricted share units, which vest at the rate of 25% per year starting June 16, 2021, was reported on Form 4 filed on June 18, 2020 as to one half of the total grant, and on Form 4 filed on June 26, 2020 as to the remaining one half, which had been granted contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved the stockholders at a meeting on June 25, 2020. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 17:56 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 50,000 | $0.62 | $31,000.00 |
DisclosureSEC source: 0001654954-21-007427 · section16.xml · nonDerivative · entry 3 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,734,696 Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 17:56 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 23,757 | $0.61 | $14,491.77 |
DisclosureSEC source: 0001654954-21-007427 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,684,696 Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 17:56 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 1,243 | $0.60 | $745.80 |
DisclosureSEC source: 0001654954-21-007427 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,660,939 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 14:45 UTC Amendment | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 50,000 | $0.62 | $31,000.00 |
DisclosureSEC source: 0001654954-21-007558 · section16.xml · nonDerivative · entry 3 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,734,696 F1 · kind: Amended to reflect open market purchases of non-derivative security. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 14:45 UTC Amendment | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 23,757 | $0.61 | $14,491.77 |
DisclosureSEC source: 0001654954-21-007558 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,684,696 F1 · kind: Amended to reflect open market purchases of non-derivative security. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 14:45 UTC Amendment | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 1,243 | $0.60 | $745.80 |
DisclosureSEC source: 0001654954-21-007558 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,660,939 F1 · kind: Amended to reflect open market purchases of non-derivative security. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 21:01 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock option (right to buy) · Derivative | 179,985 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001654954-21-007252 · section16.xml · derivative · entry 6 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,985 Underlying: Common stock · 179,985 shares Expires 2030-06-16 F6 · derivative.exercise_date: Stock options granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. The performance condition stock option grant, made June 16, 2020, vested in part on June 22, 2021, upon certification by the Compensation Committee that a defined performance objective as to 78% of the target number of stock option shares for the fiscal year ending June 30, 2021 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 21:01 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock options (right to buy) · Derivative | 497,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001654954-21-007252 · section16.xml · derivative · entry 5 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,000 Underlying: Common stock · 497,000 shares Expires 2031-06-22 F5 · derivative.exercise_date: The options vest at the rate of 25% per year, starting on June 22, 2022. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 21:01 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon stock | 108,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007252 · section16.xml · nonDerivative · entry 4 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,659,696 F4 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2021, upon certification by the Compensation Committee that a defined performance objective as to 78% of the target number of share units for the fiscal year ending June 30, 2021 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. F4 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2021, upon certification by the Compensation Committee that a defined performance objective as to 78% of the target number of share units for the fiscal year ending June 30, 2021 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 21:01 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon stock | 45,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007252 · section16.xml · nonDerivative · entry 3 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,551,081 F3 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2021, upon certification by the Compensation Committee that a defined performance objective as to 78% of the target number of share units for the fiscal year ending June 30, 2021 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. F3 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2021, upon certification by the Compensation Committee that a defined performance objective as to 78% of the target number of share units for the fiscal year ending June 30, 2021 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 21:01 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007252 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,505,782 F2 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest only if within two years of the date of grant for a twenty consecutive trading day period the price of common stock on the NYSE American for Palatin Technologies, Inc. closes at $2.00 per share or greater. F2 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest only if within two years of the date of grant for a twenty consecutive trading day period the price of common stock on the NYSE American for Palatin Technologies, Inc. closes at $2.00 per share or greater. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 21:01 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon stock | 609,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007252 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,305,782 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2022. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2022. Read SEC document |
| August 31, 2020 Filed Aug 31, 2020 20:31 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | Tax withholdingCommon Stock | 13,847 | $0.55 | $7,615.85 |
DisclosureSEC source: 0001654954-20-009651 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,380,047 F2 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll for the period ended August 31, 2020, with the per share value determined as of June 24, 2020, the date of vesting. The grant of the underlying 50,500 time-based restricted share units which vested on June 24, 2020 was reported on Form 4 filed on June 26, 2019, with a transaction date of June 24, 2019. F2 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll for the period ended August 31, 2020, with the per share value determined as of June 24, 2020, the date of vesting. The grant of the underlying 50,500 time-based restricted share units which vested on June 24, 2020 was reported on Form 4 filed on June 26, 2019, with a transaction date of June 24, 2019. Read SEC document |
| August 31, 2020 Filed Aug 31, 2020 20:31 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | Tax withholdingCommon Stock | 11,770 | $0.55 | $6,473.50 |
DisclosureSEC source: 0001654954-20-009651 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,393,894 F1 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll for the period ended August 31, 2020, with the per share value determined as of June 24, 2020, the date of vesting. The grant and vesting of the underlying 42,925 restricted share units was reported on Form 4 filed on June 26, 2020, with a transaction date of June 24, 2020. F1 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll for the period ended August 31, 2020, with the per share value determined as of June 24, 2020, the date of vesting. The grant and vesting of the underlying 42,925 restricted share units was reported on Form 4 filed on June 26, 2020, with a transaction date of June 24, 2020. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 21:00 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (Right to Buy) · Derivative | 461,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001654954-20-007013 · section16.xml · derivative · entry 3 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,500 Underlying: Common Stock · 461,500 shares Expires 2030-06-16 F3 · derivative.exercise_date: The options vest at the rate of 25% per year, starting on June 16, 2021. Options were granted June 16, 2020, contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved by the stockholders at a meeting on June 25, 2020. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 21:00 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 278,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-007013 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,291,489 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 16, 2021. Restricted share units were granted June 16, 2020, contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved by the stockholders at a meeting on June 25, 2020. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 16, 2021. Restricted share units were granted June 16, 2020, contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved by the stockholders at a meeting on June 25, 2020. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 21:00 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 42,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-007013 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,334,414 F2 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 24, 2020, upon certification by the Compensation Committee that a defined performance objective as to 85% of the target number of share units for the fiscal year ending June 30, 2020 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in licensing of Vyleesi in additional countries or regions. F2 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 24, 2020, upon certification by the Compensation Committee that a defined performance objective as to 85% of the target number of share units for the fiscal year ending June 30, 2020 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in licensing of Vyleesi in additional countries or regions. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:02 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to buy) · Derivative | 461,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001654954-20-006792 · section16.xml · derivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,500 Underlying: Common Stock · 461,500 shares Expires 2030-06-16 F2 · derivative.exercise_date: The options vest at the rate of 25% per year, starting on June 16, 2021. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:02 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 278,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-006792 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,291,489 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 16, 2021. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 16, 2021. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:18 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 50,000 | $0.87 | $43,250.00 |
DisclosureSEC source: 0001654954-19-008840 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,314,239 F1 · price: Weighted average of price paid per share on order. The reporting person hereby undertakes upon request to provide to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:38 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to buy) · Derivative | 237,500 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001654954-19-007685 · section16.xml · derivative · entry 4 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,500 Underlying: Common Stock · 237,500 shares Expires 2027-12-12 F4 · derivative.exercise_date: Vesting of performance condition stock option grant, made December 12, 2017, which vested in part on June 24, 2019, upon certification by the Compensation Committee that a defined performance objection as to 50% of the target number of share units had been achieved, the approval by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal woemen during the defined performance period. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:38 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to buy) · Derivative | 638,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001654954-19-007685 · section16.xml · derivative · entry 3 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,000 Underlying: Common Stock · 638,000 shares Expires 2029-06-24 F3 · derivative.exercise_date: Options vest at the rate of 25% per year, starting on June 24, 2020. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:38 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 202,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-007685 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,212,989 F2 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 24, 2020. F2 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 24, 2020. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:38 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 237,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-007685 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,010,989 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 12, 2017, vested in part on June 24, 2019 upon certification by the Compensation Committee that a defined performance objective as to 50% of the target number of share units had been achieved, the approval by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal women during the defined performance period. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 12, 2017, vested in part on June 24, 2019 upon certification by the Compensation Committee that a defined performance objective as to 50% of the target number of share units had been achieved, the approval by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal women during the defined performance period. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 21:21 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 15,000 | $0.77 | $11,550.00 |
DisclosureSEC source: 0001654954-18-012958 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,918,239 Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 21:21 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | PurchaseCommon Stock | 5,000 | $0.76 | $3,805.50 |
DisclosureSEC source: 0001654954-18-012958 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,903,239 Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 20:25 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001654954-18-007091 · section16.xml · derivative · entry 4 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2027-12-12 F4 · derivative.exercise_date: Vesting of performance condition stock option grant, made December 12, 2017, which vested in part on June 26, 2018, upon certification by the Compensation Committee that a defined performance objective as to 30% of the target number of share units had been achieved, the acceptance for filing by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal women during the defined performance period. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 20:25 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to buy) · Derivative | 454,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007091 · section16.xml · derivative · entry 3 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,000 Underlying: Common Stock · 454,000 shares Expires 2028-06-26 F3 · derivative.exercise_date: Options vest at the rate of 25% per year, starting on June 26, 2019. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 20:25 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 303,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007091 · section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,687,489 F2 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest as to 50% June 26, 2019 and as to the remaining shares on June 26, 2020. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. F2 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest as to 50% June 26, 2019 and as to the remaining shares on June 26, 2020. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 20:25 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007091 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,384,489 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 12, 2017, vested in part on June 26, 2018, upon certification by the Compensation Committee that a defined performance objective as to 30% of the target number of share units had been achieved, the acceptance for filing by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal women during the defined performance period. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 12, 2017, vested in part on June 26, 2018, upon certification by the Compensation Committee that a defined performance objective as to 30% of the target number of share units had been achieved, the acceptance for filing by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal women during the defined performance period. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:17 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to acquire) · Derivative | 575,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001654954-17-011586 · section16.xml · derivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2027-12-12 F2 · derivative.exercise_date: Options vest at the rate of 25% per year, starting on December 12, 2018. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:17 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 575,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-011586 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,127,239 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on December 12, 2018. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on December 12, 2018. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:03 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantStock Option (right to acquire) · Derivative | 859,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001654954-17-005800 · section16.xml · derivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 859,000 Underlying: Common Stock · 859,000 shares Expires 2027-06-20 F2 · derivative.exercise_date: Options vest at the rate of 25% per year, starting on June 20, 2018. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:03 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 545,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-005800 · section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,671,989 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest as to 50% June 20, 2018 and as to the remaining shares on June 20, 2019. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest as to 50% June 20, 2018 and as to the remaining shares on June 20, 2019. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 20:23 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | Tax withholdingCommon Stock | 28,899 | $0.36 | $10,403.64 |
DisclosureSEC source: 0001354488-17-000573 · issuerdirect_section16.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,126,989 F3 · shares: Shares withheld by the issuer to pay employee withholding taxes, valued at $0.36 per share, the closing price on 06/09/2017, the business day immediately preceding the vesting date. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 20:23 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | Exercise / conversionCommon Stock | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-17-000573 · issuerdirect_section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued on vesting of restricted stock units. F2 · price: Each restricted stock unit represented the right to receive on vesting, without further payment, one share of common stock. Read SEC document |
| February 24, 2017 Filed Feb 24, 2017 17:30 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Disposition to issuerRestricted Stock Units · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-011041 · v460295_form4.xml · derivative · entry 4 WILLS STEPHEN T · CIK 0001103883 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,500 shares Expires not disclosed F5 · derivative.exercise_price: Upon the Effective Time, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings. F7 · price: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration. F5 · derivative.exercise_date: Upon the Effective Time, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings. F5 · derivative.expiration_date: Upon the Effective Time, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings. Read SEC document |
| February 24, 2017 Filed Feb 24, 2017 17:30 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Disposition to issuerStock Option (right to buy) · Derivative | 29,375 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001144204-17-011041 · v460295_form4.xml · derivative · entry 3 WILLS STEPHEN T · CIK 0001103883 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,375 shares Expires not disclosed F3 · derivative.exercise_price: Represents the weighted average exercise price for in-the-money stock options, as described in a Schedule TO and the Issuer's Schedule 14D-9, each as filed with the Securities and Exchange Commission on January 25, 2017, pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share (the "Offer"). F6 · price: The options were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration. F4 · derivative.exercise_date: In connection with the expiration of the Offer and the subsequent closing of the merger pursuant to the terms of the Merger Agreement, all outstanding stock options became fully vested and exercisable on such date. Each stock option held by the reporting person was then cancelled in exchange for a cash payment representing the difference between the exercise price of such option and $7.00 per share, payable without any interest thereon and subject to any required tax withholdings. F4 · derivative.expiration_date: In connection with the expiration of the Offer and the subsequent closing of the merger pursuant to the terms of the Merger Agreement, all outstanding stock options became fully vested and exercisable on such date. Each stock option held by the reporting person was then cancelled in exchange for a cash payment representing the difference between the exercise price of such option and $7.00 per share, payable without any interest thereon and subject to any required tax withholdings. Read SEC document |
| February 24, 2017 Filed Feb 24, 2017 17:30 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Disposition to issuerCommon Stock | 27,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-011041 · v460295_form4.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 F2 · shares: Represents shares of the Issuer's common stock received upon the vesting of 27,500 restricted stock units, as described herein. F4 · price: In connection with the expiration of the Offer and the subsequent closing of the merger pursuant to the terms of the Merger Agreement, all outstanding stock options became fully vested and exercisable on such date. Each stock option held by the reporting person was then cancelled in exchange for a cash payment representing the difference between the exercise price of such option and $7.00 per share, payable without any interest thereon and subject to any required tax withholdings. Read SEC document |
| February 24, 2017 Filed Feb 24, 2017 17:30 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Disposition to issuerCommon Stock | 147,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-011041 · v460295_form4.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2017, by and among the Issuer, Integra Derma, Inc. and Integra LifeSciences Holdings Corporation (the "Merger Agreement"), as of the Effective Time (as defined in the Merger Agreement), the shares of the Issuer's common stock were converted into the right to receive $7.00 per share to the reporting person in cash. Read SEC document |
| February 10, 2017 Filed Feb 16, 2017 19:15 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Exercise / conversionStock Option (right to buy) · Derivative | 4,375 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001144204-17-009666 · v459887_form4.xml · derivative · entry 3 WILLS STEPHEN T · CIK 0001103883 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The options were originally granted in consideration of the reporting person's services to the issuer and without payment of cash. F2 · derivative.exercise_date: A total of 35,000 of the options were granted pursuant to the issuer's stock option plan on March 1, 2007. Options for 25% of the shares vested immediately and options for the remaining shares vested at the rate of 25% per year starting on February 22, 2008.The revised total of 4,375 options reflects the issuer's 1-for-8 reverse split effective January 1, 2010. Read SEC document |
| February 10, 2017 Filed Feb 16, 2017 19:15 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Tax withholdingCommon Stock | 4,000 | $7.00 | $28,000.00 |
DisclosureSEC source: 0001144204-17-009666 · v459887_form4.xml · nonDerivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,076 F1 · shares: Shares delivered in connection with the cashless exercise of 4,375 options, previously granted pursuant to the issuer's stock option plan, at an exercise price of $6.40, as reported herein. Read SEC document |
| February 10, 2017 Filed Feb 16, 2017 19:15 UTC | DERMA SCIENCES, INC. DSCI · Entity 178548 | Exercise / conversionCommon Stock | 4,375 | $6.40 | $28,000.00 |
DisclosureSEC source: 0001144204-17-009666 · v459887_form4.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares delivered in connection with the cashless exercise of 4,375 options, previously granted pursuant to the issuer's stock option plan, at an exercise price of $6.40, as reported herein. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 21:31 UTC | PALATIN TECHNOLOGIES INC PTN · Entity 7649 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-17-000212 · issuerdirect_section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,939,041 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 8, 2015, vested on February 2, 2017, upon the Issuer entering into a collaboration agreement for North America for its Rekynda? (bremelanotide) product. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 8, 2015, vested on February 2, 2017, upon the Issuer entering into a collaboration agreement for North America for its Rekynda? (bremelanotide) product. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.